• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(F146-1740)

1

Identification

F146-1740 F146-1740
Name F146-1740
Formula C24H21N3O
MW 367.44
CAS No.
EINECS
Smiles C1C=CC(C2C(C(N(C3C=C(C)C(C)=CC=3)C)=O)=C3C=CC=CC3=NN=2)=CC=1
Synonyms
InChI InChI=1S/C24H21N3O/c1-16-13-14-19(15-17(16)2)27(3)24(28)22-20-11-7-8-12-21(20)25-26-23(22)18-9-5-4-6-10-18/h4-15H,1-3H3
2

Introduction

F146-1740 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 16.0±2.3% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100692273

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Neurological Disease
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of F146-1740

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

F146-1740

Tags: buy F146-1740 IC50 | F146-1740 price | F146-1740 cost | F146-1740 solubility | F146-1740 purchase | F146-1740 manufacturer | F146-1740 research buy | F146-1740 order | F146-1740 MSDS | F146-1740 chemical structure | F146-1740 Storage condition | F146-1740 molecular weight | F146-1740 mw | F146-1740 datasheet | F146-1740 supplier | F146-1740 cell line | F146-1740 NMR | F146-1740 MS | F146-1740 IR | F146-1740 solubility | F146-1740 Safe information | F146-1740 Qc and Spectral Information | F146-1740 Clinical Information | F146-1740 Clinical Trial | F146-1740 Route of Synthesis | F146-1740 storage condition | F146-1740 diseases and conditions | F146-1740 flash point | F146-1740 boiling point | F146-1740 melting point | F146-1740 storage condition | F146-1740 brand